Clinical Trial Update: A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for Tulmimetostat DZR123 (CPI-0209) in adults with advanced solid tumors and various lymphomas. The study is in Phase 1/Phase 2 and curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Diffuse Large B-cell Lymphoma
• Endometrial Cancer
• Malignant Mesothelioma
• Ovarian Clear Cell Carcinoma
• Solid Tumors
• T-cell Lymphoma

Drugs mentioned

• Tulmimetostat DZR123 (CPI-0209) (Tulmimetostat DZR123)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Advanced Solid Tumor, Diffuse Large B Cell Lymphoma | Phase 1, Phase 2 | Status: RECRUITING